These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. How many samples are needed to infer truly clonal mutations from heterogenous tumours? Opasic L; Zhou D; Werner B; Dingli D; Traulsen A BMC Cancer; 2019 Apr; 19(1):403. PubMed ID: 31035962 [TBL] [Abstract][Full Text] [Related]
4. [1 of the pathways for normalization of populations of malignant cells]. Shuklinov VA Tsitologiia; 1985 Mar; 27(3):268-75. PubMed ID: 3887700 [TBL] [Abstract][Full Text] [Related]
9. Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. Sayagués JM; Abad Mdel M; Melchor HB; Gutiérrez ML; González-González M; Jensen E; Bengoechea O; Fonseca E; Orfao A; Muñoz-Bellvis L J Pathol; 2010 Jul; 221(3):308-19. PubMed ID: 20527024 [TBL] [Abstract][Full Text] [Related]
10. The challenge of intratumour heterogeneity in precision medicine. Seoane J; De Mattos-Arruda L J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605 [TBL] [Abstract][Full Text] [Related]
11. [The bewildering complexity of cancer]. Jordan B Med Sci (Paris); 2011; 27(8-9):781-6. PubMed ID: 21880268 [No Abstract] [Full Text] [Related]
12. Cancer heterogeneity--a multifaceted view. De Sousa E Melo F; Vermeulen L; Fessler E; Medema JP EMBO Rep; 2013 Aug; 14(8):686-95. PubMed ID: 23846313 [TBL] [Abstract][Full Text] [Related]
13. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Brioli A; Melchor L; Cavo M; Morgan GJ Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032 [TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267 [TBL] [Abstract][Full Text] [Related]
15. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. Jones AM; Mitter R; Springall R; Graham T; Winter E; Gillett C; Hanby AM; Tomlinson IP; Sawyer EJ; J Pathol; 2008 Apr; 214(5):533-44. PubMed ID: 18288784 [TBL] [Abstract][Full Text] [Related]
16. On the karyotypic origin and evolution of cancer cells. Nicholson JM; Duesberg P Cancer Genet Cytogenet; 2009 Oct; 194(2):96-110. PubMed ID: 19781442 [TBL] [Abstract][Full Text] [Related]
17. A new model for oncogenesis. From tumour immunology to a mathematical approach of oncogenesis. Den Otter W; Koten JW; Derkinderen DJ Anticancer Res; 1986; 6(3 Pt B):509-14. PubMed ID: 3740800 [TBL] [Abstract][Full Text] [Related]
18. Population genetics of cancer cell clones: possible implications of cancer stem cells. Naugler CT Theor Biol Med Model; 2010 Nov; 7():42. PubMed ID: 21062473 [TBL] [Abstract][Full Text] [Related]
19. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. Fratta E; Sigalotti L; Colizzi F; Covre A; Nicolay HJ; Danielli R; Fonsatti E; Altomonte M; Calabrò L; Coral S; Maio M J Cell Physiol; 2010 May; 223(2):352-8. PubMed ID: 20127705 [TBL] [Abstract][Full Text] [Related]
20. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis. Koten JW; Neijt JP; Zonnenberg BA; Den Otter W Anticancer Res; 1993; 13(4):1179-82. PubMed ID: 8352541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]